| Autor: |
Mehnmet Altay Unal, Omur Besbinar, Hasan Nazir, Gokce Yagmur Summak, Fatma Bayrakdar, Lucia Gemma Delogu, Tambay Taskin, Sibel Aysil Ozkan, Kamil Can Akcali, Acelya Yilmazer |
| Rok vydání: |
2022 |
| Předmět: |
|
| DOI: |
10.1101/2022.01.11.475889 |
| Popis: |
Since the first cases the coronavirus disease caused by SARS-CoV-2 (COVID-19) reported in December 2019, worldwide continuous efforts have been placed both for the prevention and treatment of this infectious disease. As new variants of the virus emerge, the need for an effective antiviral treatment continues. The concept of preventing SARS-CoV-2 on both pre-entry and post-entry stages has not been much studied. Therefore, we compared the antiviral activities of three antiviral drugs which have been currently used in the clinic. In silico docking analyses and in vitro viral infection in Vero E6 cells were performed to delineate their antiviral effectivity when used alone or in combination. Both in silico and in vitro results suggest that the combinatorial treatment by favipiravir and umifenovir or camostat mesylate has more antiviral activity against SARS-CoV-2 rather than single drug treatment. These results suggest that inhibiting both viral entry and viral replication at the same time is much more effective for the antiviral treatment of SARS-CoV-2. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
